← Back to headlines
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
AbbVie has announced its acquisition of Apogee Therapeutics for $10.9 billion in cash, aiming to bolster its immunology pipeline with next-generation inflammatory disease drugs. The deal caused Apogee's stock to surge significantly.
22 Jun, 11:11 — 22 Jun, 14:04
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (59/100)5 sources33/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left2
Left (2)
Yahoocnbc
Center2
Center (2)
FTbloomberg
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US4UK1
Sources
Showing 5 of 5 sources
bloombergHigh17d ago
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash - Bloomberg.com
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash Bloomberg.com
Read full article →FTVery High17d ago
AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug
Drugmaker’s largest deal in more than half a decade comes amid surge of M&A in sector
Read full article →cnbcMostly Factual17d ago
AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in more than five years.
Read full article →YahooMostly Factual17d ago
AbbVie to acquire Apogee Therapeutics in $10.9B deal
Read full article →seeking-alphaMixed17d ago
As AbbVie eyes Apogee, these biotech stocks earn the highest Quant ratings
Read full article →Coverage Timeline
First report: bloomberg · 22 Jun, 11:11|Full coverage: 5 · 3h|Window: 3h
Left-leaningCenterRight-leaning
